Duvelisib (COPIKTRA)
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL); Relapsed/Refractory Follicular Lymphoma (FL)
Key Facts
About Secura Bio
Secura Bio is a private, commercial-stage biotech company that acquires and develops oncology therapies, primarily for hematologic malignancies. Its current commercial asset is duvelisib (COPIKTRA), a PI3K inhibitor for certain leukemias and lymphomas, which it acquired and is managing through a restricted distribution program. The company's strategy leverages a veteran leadership team with proven commercial success in crowded markets, focusing on optimizing the path of existing drugs and identifying areas for further clinical development. Secura Bio operates with a lean, virtual model, emphasizing strategic partnerships and a targeted commercial approach.
View full company profile